COVID-19 Vaccine Should Demonstrate At Least 50% Effectiveness, US FDA Says
Executive Summary
Guidance on COVID-19 vaccine development and licensure appears to set a precedent in specifying the clinical efficacy rate for a product approval; agency also takes accelerated approval off the table for now and says emergency use authorization may be granted only after safety and efficacy have been demonstrated.
You may also be interested in...
US FDA Still Discussing Ideas For Pediatric Development Of COVID-19 Vaccines
J&J CEO Gorsky says the agency is working with sponsors to ensure the proper data is gathered to make the vaccine available in children.
US FDA Sets Immunogenicity Bar High For Changes To COVID-19 Vaccines
Modified vaccines targeted at new SARS-CoV-2 variants must generate immune response rates not more than 10% below those of the original vaccine, agency says in one of a suite of guidances on medical product development to address variants.
COVID Trial Diversity: What Participants In The Vaccine Phase III Studies Look Like
Although differences in how sponsors have publicly disclosed demographic data for their enrolled trials make cross-study comparisons difficult, in general trial enrollment of Black and Hispanic participants has ranged from 10%-19% and 11%-45%, respectively, with one-quarter to one-third of study subjects falling into older age groups.